Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $5.35 USD
Change Today +0.1868 / 3.62%
Volume 28.2K
CFRX On Other Exchanges
Symbol
Exchange
NASDAQ CM
Stuttgart
As of 2:53 PM 07/2/15 All times are local (Market data is delayed by at least 15 minutes).

contrafect corp (CFRX) Snapshot

Open
$5.23
Previous Close
$5.16
Day High
$5.40
Day Low
$5.15
52 Week High
04/15/15 - $6.24
52 Week Low
12/10/14 - $2.50
Market Cap
108.7M
Average Volume 10 Days
81.5K
EPS TTM
$-10.20
Shares Outstanding
20.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CONTRAFECT CORP (CFRX)

Related News

No related news articles were found.

contrafect corp (CFRX) Related Businessweek News

No Related Businessweek News Found

contrafect corp (CFRX) Details

ContraFect Corporation, a biotechnology company, focuses on discovering and developing therapeutic protein and antibody products for life-threatening and drug-resistant infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin that is in Phase 1 human clinical trials for the treatment of Staph aureus bacteremia, including endocarditis caused by methicillin-sensitive or methicillin-resistant Staph aureus; and CF-404, a combination of human monoclonal antibodies for the treatment of life-threatening seasonal and pandemic varieties of influenza. The company was founded in 2008 and is headquartered in Yonkers, New York.

21 Employees
Last Reported Date: 03/26/15
Founded in 2008

contrafect corp (CFRX) Top Compensated Officers

Chief Executive Officer, Principal Financial ...
Total Annual Compensation: $712.5K
Chief Scientific Officer and Senior Vice Pres...
Total Annual Compensation: $427.8K
Consultant
Total Annual Compensation: $380.9K
Compensation as of Fiscal Year 2014.

contrafect corp (CFRX) Key Developments

ContraFect Corporation Announces Executive Appointments

ContraFect Corporation appointed Steven C. Gilman, PhD, to its Board of Directors where he will assume the role of Executive Chairman. Dr. Gilman was Executive Vice President, Research & Development and Chief Scientific Officer at Cubist Pharmaceuticals, until its acquisition by Merck & Co. in January 2015. Sol Barer, PhD, will assume the title of Lead Independent Director.

ContraFect Corporation Announces Earnings Results for the First Quarter of 2015

ContraFect Corporation announced earnings results for the first quarter of 2015. The company reported a first quarter of 2015 net loss per share of $0.24, narrower than the loss of $5.15 per share reported in the same period a year ago. The results were impacted by number of shares outstanding, with 20.2 million in first quarter of 2015 compared to 1 million in first quarter of 2014. The company reported no first quarter revenues.

ContraFect Corporation Presents at Boston CEO Conference, May-27-2015 11:20 AM

ContraFect Corporation Presents at Boston CEO Conference, May-27-2015 11:20 AM. Venue: Four Seasons Hotel, 200 Boylston Street, Boston, MA 02116, United States. Speakers: Julia P. Gregory, Chief Executive Officer, Principal Financial Officer and Director.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CFRX:US $5.35 USD +0.1868

CFRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CFRX.
View Industry Companies
 

Industry Analysis

CFRX

Industry Average

Valuation CFRX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 5.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CONTRAFECT CORP, please visit www.contrafect.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.